

RECEIVED.
SECRETARY OF THE SENATE
04 AUG 16 PM 2:10

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Biotechnology Industry Organization			
2. Address <input type="checkbox"/> Check if different than previously reported 1225 Eye Street NW, Suite 400			
3. Principal Place of Business (if different from line 2) Washington DC 20005 City: State/zip (or Country)			
4. Contact Name David Burt	Telephone (202) 962-9200	E-mail (optional) dburt@bio.org	5. Senate ID # 6245-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 3250500

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☒ OR Year End (July 1-December) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇌ Termination Date _____

11. No Lobbying A ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇌ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇌ \$ <u>2,520,000</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(1) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Internal Revenue Code</p>
--	---



Signature _____ Date _____

Printed Name and Title _____ Michael Werner, Chief of Policy _____

LD-2 (REV. 4/03)

PAGE 1 of 2

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code ACC (one per page)

16. Specific lobbying issues

- H.R. 1372, S. 979 Broad Based Stock Option Plan Transparency Act
- H.R. 3574, S. 1890 Stock Option Accounting Reform Act
- H.R. 286, S. 206 To Amend the Internal Revenue Code of 1986 to Clarify the Treatment of incentive Stock Options & Employee Stock Purchase Plans
- March 31, 2004 FASB Proposal on Stock Option Expensing

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
- Senate
- Treasury
- Security & Exchange Commission
- White House
- IRS

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Morrie Ruffin	Vice President, Bus Dev & Emerging Companies
Steve Lawton	General Counsel
Libby Solon	Director, Government Relations
Peter Norman	Manager, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature



Date

8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 2 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific lobbying issues

- H.R. 4766 Agriculture Appropriations
 - H.R. 4561 To establish a Federal interagency task force to promote the benefits, safety and potential uses of agricultural biotechnology
 - H.R. 4693 Seed Availability and Competition Act of 2004
 - H.R. 4454 Ecoterrorism Prevention Act of 2004
 - S. 2546 Genetically Engineered Foods Act
 - H.R. 1950 Foreign Relations Authorization Act, Fiscal Years 2004 & 2005
 - Proposed Policy re: Adventitious Presence

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - US Trade Representative
 - Senate - EPA
 - FDA
 - USDA
 - Department of State

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
L. Val Giddings	Vice President, Food and Agriculture
Mike Phillips	VP, Food and Ag, Science and Reg Affairs
Sharon Cohen	Vice President, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature Michael Warner Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 3 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific lobbying issues

- H.Res. 252 Expressing the sense of the House of Representatives supporting the USA in its efforts within the WTO to end the European Union's protectionist and discriminatory trade practices of the past 5 years regarding agricultural biotechnology

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
- Senate
- FDA
- USDA
- Department of State
- US Trade Representative
- EPA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
L. Val Giddings	Vice President, Food and Agriculture
Mike Phillips	VP, Food and Ag, Science and Reg Affairs
Sharon Cohen	Vice President, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 4 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

- Appropriations Bills (H.R. 4766 Agriculture; H.R. 4754 Commerce, Justice, State; H.R. 4613 & S. 2559 Defense; H.R. 4614 Energy & Water; H.R. 4567 & S. 2537 Homeland Security; H.R. 4568 Interior; H.R. 4755 & S. 2606 Legislative Branch)
 - Supplemental Appropriations Budget
 - PTO Fee Bill

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - Office of Standards and Technologies
 - Senate - USDA
 - FDA - EPA
 - HHS - Dept of Energy
 - OMB - Department of Commerce

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Steve Lawton	General Counsel
Libby Solon	Director, Government Relations
Jennifer Berzok	Director, Government Relations
Peter Norman	Manager, Government Relations
L. Val Giddings	Vice President, Food and Agriculture
Brent Erickson	Vice President, Industrial and Environmental
Michael Werner	Chief of Policy

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 5 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

- Appropriations Bills (H.R. 4766 Agriculture; H.R. 4754 Commerce, Justice, State; H.R. 4613 & S. 2559 Defense; H.R. 4614 Energy & Water; H.R. 4567 & S. 2537 Homeland Security; H.R. 4568 Interior; H.R. 4755 & S. 2606 Legislative Branch)
 - Supplemental Appropriations Budget
 - PTO Fee Bill

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - Office of Standards and Technologies
 - Senate - USDA
 - FDA - EPA
 - HHS - Dept of Energy
 - OMB - Department of Commerce

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Lila Feisee	Director, Intellectual Property

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 6 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

- H.R. 1561 United States Patent and Trademark Fee Modernization Act of 2004
- H.R. 2391 CREATE Act
- H.R. 4754 Commerce, Justice, State Appropriations
- Post Grant Opposition
- Human Cloning Patent Amendment

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
- Senate
- PTO
- NIH
- Commerce Office of Science Policy
- Department of State
- HHS
- US Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Michael Werner	Chief of Policy
Jennifer Berzok	Director, Government Relations
Libby Solon	Director, Government Relations
Steve Lawton	General Counsel
Lila Feisee	Director, Intellectual Property
Peter Norman	Manager, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 7 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code DEF (one per page)

16. Specific lobbying issues

- S.15 Project Bioshield Act of 2004
 - H.R. 4613, S. 2559 Defense Appropriations
 - H.R. 4454 Ecoterrorism Prevention Act of 2004
 - P.L. 108-136 Defense Authorization Act
 - Biobased Purchasing Policy
 - Biothreat Countermeasures

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - FDA
 - Senate - HHS
 - Dept of Defense - White House
 - Dept of Homeland Security
 - Office of Vice President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carl Feldbaum	President
Sharon Cohen	Vice President, Government Relations
Brent Erickson	Vice President, Industrial & Environmental
L. Val Giddings	Vice President, Food and Agriculture
Steve Lawton	General Counsel
Gillian Woollett	Vice President, Regulatory Affairs
Jennifer Berzok	Director, Government Relations
Michael Werner	Chief of Policy

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Vetter, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 8 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code ENG (one per page)

16. Specific lobbying issues

- H.R. 6, H.R. 1644, S. 1005 Energy Policy Act of 2003
 - Bioenergy Legislation
 - Funding for Research & Development of Advanced Biotech and Energy and Chemicals Production
 - Agricultural Policy
 - Biobased Purchasing Policy


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
 - Senate
 - Dept of Commerce
 - Dept of Energy
 - Dept of Defense
 - Dept of Agriculture
 - White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Brent Erickson	Vice President, Industrial and Environmental

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/04

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 9 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

16. Specific lobbying issues

- H.R. 4766 Agriculture Appropriations
- H.R. 4665 Importation of Safe Food Act of 2004
- H.R. 4651 To establish an Federal interagency task force to promote the benefits, safety, and potential uses of agricultural biotechnology
- H.R. 2352 American Horse Slaughter Prevention Act of 2004
- S. 2546 Genetically Engineered Foods Act
- Proposed Policy re: Adventitious Presence

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
- Senate
- EPA
- USDA
- FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
L. Val Giddings	Vice President, Food and Agriculture
Mike Phillips	VP, Food and Ag, Science and Reg Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 10 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

16. Specific lobbying issues

- H.Res. 252 Expressing the sense of the House of Representatives supporting the USA in its efforts within the WTO to end the European Union's protectionist and discriminatory trade practices of the past 5 years regarding agricultural biotechnology

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
- Senate
- EPA
- USDA
- FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
L. Val Giddings	Vice President, Food and Agriculture
Mike Phillips	VP, Food and Ag, Science and Reg Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 11 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HOM (one per page)

16. Specific lobbying issues

- S. 15 Project Bioshield Act of 2004
 - H.R. 4454 Ecoterrorism Prevention Act of 2004
 - Biothreat Countermeasures

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - White House
 - Senate
 - Dept of Defense
 - USDA
 - FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Steve Lawton	General Counsel
Michael Werner	Chief of Policy
Jennifer Berzok	Director, Government Relations
Brent Erickson	Vice President, Industrial and Environmental

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/04

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 12 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- H.R. 4682 Stem Cell Research Enhancement Act of 2004
 - H.R. 3960 Stem Cell Replenishment Act of 2004
 - H.R. 4531 Ronald Reagan Memorial Stem Cell Research Act of 2004
 - S. 1053 Genetic Nondiscrimination Act of 2003
 - H.R. 3594 Protection for Participants in Research Act of 2003
 - Labor HHS Appropriations Act - Vaccines
 - Clinical Trial Information Disclosure
 - Bayh-Dole - March-in Rights

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - Dept of State
 - Senate - Center for Disease Control
 - HHS - NIST (Dept of Commerce)
 - NIH - White House
 - FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Michael Werner	Chief of Policy
Michael Losow	Director of Outreach
Lila Feisee	Director, Intellectual Property
Jennifer Berzok	Director, Government Relations
Gillian Woollett	Vice President, Regulatory Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rec. 4/03)

Page 13 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- NIH Conflict of Interest
- FDA Review Practices
- Cell, Gene, and Tissue Therapy
- Pharmacogenomics
- PDUFA Implementation

17. House(s) of Congress and Federal agencies contacted ☐ Check if None


- House
- Senate
- HHS
- NIH
- FDA
- Dept of State
- Center for Disease Control
- NIST (Dept of Commerce)
- White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Michael Werner	Chief of Policy
Michael Losow	Director of Outreach
Lila Feisee	Director, Intellectual Property
Jennifer Berzok	Director, Government Relations
Gillian Woollett	Vice President, Regulatory Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature



Date

8/16/2004

Printed Name and Title Michael Werner, Chief of Policy`

Form LD-2 (Rec. 4/03)

Page 14 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- S. 1950 Medicare Prescription Drug Savings Act of 2003
- S. 2652, S. 2257, H.R. 3767 Medicare Prescription Drug Savings and Choice Act of 2004
- S. 2343 Medicare Modernization Improvement Act of 2004
- S. 2667 Medicare Replacement Drug Demonstration Project Improvement Act of 2004
- H.R. 2473 Medicare Prescription Drug and Modernization Act of 2003
- S. 222 Medicaid and CHIP Safety Net Preservation Act of 2004
- MMA - Part D Drug Benefit

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - White House
- Senate
- HHS
- CMS
- OMB

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carl Feldbaum	President
Michael Werner	Chief of Policy
Sharon Cohen	Vice President, Government Relations
Libby Solon	Director, Government Relations
Jennifer Berzok	Director, Government Relations
Peter Norman	Manager, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael V. Moran, Chief of Policy

Form LD-2 (Rec. 4/03)

Page 15 of

Registrant Name Biotechnology Industry Organization

Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

- H.R. 4151 Brian Lykins Human Tissue Transplant Safety Act of 2003
- H.R. 4790 Drug Importation Promotion and Safety Act
- S. 2493 Safe IMPORT Act of 2004
- H.R. 3710 To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs
- S. 2307 Reliable Entry for Medicines at Everyday Discounts Through Importation with Effective Safeguards Act of 2004
- S. 2328 Pharmaceutical Market Access and Drug Safety Act of 2004
- FDA Issues including: Post Marketing, Clinical Trials, Drug Reviews, Drug Manufacturing, and Counterfeiting

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

- House - White House
- Senate
- HHS
- FDA
- OMB

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carl Feldbaum	President
Michael Werner	Chief of Policy
Sharon Cohen	Vice President, Government Relations
Libby Solon	Director, Government Relations
Jennifer Berzok	Director, Government Relations
Steve Lawton	General Counsel
Gillian Woollett	Vice President, Regulatory Affairs
Wendy Taylor	Director, Regulatory Affairs & Bioethics

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Signature _____


Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 16 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

- H.R. 4151 Brian Lykins Human Tissue Transplant Safety Act of 2003
- H.R. 4790 Drug Importation Promotion and Safety Act
- S. 2493 Safe IMPORT Act of 2004
- H.R. 3710 To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs
- S. 2307 Reliable Entry for Medicines at Everyday Discounts Through Importation with Effective Safeguards Act of 2004
- S. 2328 Pharmaceutical Market Access and Drug Safety Act of 2004
- FDA Issues including; Post Marketing, Clinical Trials, Drug Reviews, Drug Manufacturing, and Counterfeiting

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - White House
- Senate
- HHS
- FDA
- OMB

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Lila Feisee	Director, Intellectual Property
Michael Losow	Director of Outreach

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature _____



Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 17 of

15. General issue area code SCI (one per page)

- H.R. 4149, S. 2384 To amend the Small Business Act to permit business concerns that are owned by venture capital operating companies or pension plans to participate in the Small Business Innovation Research Program
- H.R. 4656 Nanomanufacturing Investment Act of 2004
- H.R. 4503 Energy Policy Act of 2004

- House
- Senate
- SBA
- White House

Name	Covered Official Position (if applicable)
Carl Feldbaum	President
Sharon Cohen	Vice President, Government Relations
Morrie Ruffin	Vice President, Bus Dev & Emerging Companies
Michael Werner	Chief of Policy
Libby Solon	Director, Government Relations
Steve Lawton	General Counsel
Peter Norman	Manager, Government Relations
Brent Erickson	Vice President, Industrial and Environmental

Signature Mulhal Tidener Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 18 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code SMB (one per page)

16. Specific lobbying issues

- H.R. 4149, S. 2384 To amend the Small Business Act to permit business concerns that are owned by venture capital operating companies or pension plans to participate in the Small Business Innovation Research Program
- H.R. 2802 Small Business Reauthorization and Manufacturing Revitalization Act of 2003

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House
- Senate
- SBA
- White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Morrie Ruffin	Vice President, Bus Dev & Emerging Companies
Michael Werner	Chief of Policy
Libby Solon	Director, Government Relations
Peter Norman	Manager, Government Relations
Carl Feldbaum	President

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 19 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

- H.R. 2968, S. 1773 Biotechnology Future Investment Act of 2003
 - H.R. 3574, S. 1890 Stock Option Accounting Reform Act
 - H.R. 1308 Tax Relief, Simplification and Equity Act of 2003
 - H.R. 2931 Orphan Drug Tax Credit Act of 2003
 - H.R. 4520, S. 1637 Jumpstart Our Business Strength (JOBS) Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House - IRS
 - Senate
 - Treasury
 - Security & Exchange Commission
 - White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sharon Cohen	Vice President, Government Relations
Morrie Ruffin	Vice President, Bus Dev & Emerging Companies
Michael Werner	Chief of Policy
Libby Solon	Director, Government Relations
Peter Norman	Manager, Government Relations
Michael Losow	Director of Outreach

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/16/2004

Printed Name and Title Michael Wether, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 20 of

Registrant Name Biotechnology Industry Organization Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

- WTO Case on Moratorium in European Union
- WTO Case on Traceability and Labeling
- General WTO Issues
- Importation Legislation
- Trade Related Intellectual Property Agreements
- Harmonization Efforts

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- | | |
|--------------------------------------|--------------------------------|
| - House | - EPA |
| - Senate | - USDA |
| - Executive Office of President | - FDA |
| - Executive Office of Vice President | - US Patent & Trademark Office |
| - Dept of State | - US Trade Representative |

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
L. Val Giddings	Vice President, Food and Agriculture
Mike Phillips	VP, Food and Ag, Science & Regulatory Affairs
Sharon Cohen	Vice President, Government Relations
Michael Werner	Chief of Policy
Brent Erickson	Vice President, Industrial and Environmental
Lila Feisee	Director, Intellectual Property

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date _____

Printed Name and Title _____

Form LD-2 (Rec. 4/03)

Page 21 of

Registrant Name Biotechnology Industry Organization Client Name _____

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

- Sharon Cohen
- Matthew Lyons
- Peter Norman
- Gillian Woollett
- Wendy Taylor

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Overseas per client

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature  Date 8/16/2004

Printed Name and Title Michael Werner, Chief of Policy

Form LD-2 (Rev. 4/03)

Page 22 of